Cargando…

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus

Objective: To determine the prevalence of adverse health-related quality of life (HRQoL) outcomes in patients with SLE who achieved an adequate clinical response after a 52-week long standard therapy plus belimumab or placebo, and identify contributing factors. Methods: We included patients who met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, Alvaro, Qiu, Victor, Cederlund, Arvid, Borg, Alexander, Lindblom, Julius, Emamikia, Sharzad, Enman, Yvonne, Lampa, Jon, Parodis, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085308/ https://www.ncbi.nlm.nih.gov/pubmed/33937290 http://dx.doi.org/10.3389/fmed.2021.651249

Ejemplares similares

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023)

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
por: Borg, Alexander, et al.
Publicado: (2021)

How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2022)

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
por: Hua, Nicole, et al.
Publicado: (2023)

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2021)

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
por: Lindblom, Julius, et al.
Publicado: (2022)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2022)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature
por: Palazzo, Leonardo, et al.
Publicado: (2022)

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
por: Dey, Mrinalini, et al.
Publicado: (2021)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
por: Parodis, Ioannis, et al.
Publicado: (2023)

COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
por: Giannopoulou, Nefeli, et al.
Publicado: (2023)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice
por: Stock, Ariel D., et al.
Publicado: (2015)

Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult
por: Mao, Qiu-Xia, et al.
Publicado: (2017)

Prediction of prognosis and renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2020)

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

A Case of Pseudo-Pseudo Meigs’ Syndrome Despite Optimized Immunosuppressive Therapy for Systemic Lupus Erythematosus
por: Dang, Varun, et al.
Publicado: (2023)

Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
por: Naveen, R, et al.
Publicado: (2022)

Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus
por: Bruera, Sebastian, et al.
Publicado: (2022)

Lupus Erythematosus
por: Gardiner, Frederick
Publicado: (1923)

Lupus Erythematosus
por: Ravogli, A.
Publicado: (1887)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o17jsu9jqsf5ahjq9jqss1u6i2